Trabuco Extinction

Gunpowder took the place of many weapons that many people had not heard of when it was created. When gunpowder was created, people had a weapon available to them that was able to do a whole lot more damage than the weapons they had been accustomed to using. Switching from their old weapons to a new faster weapon did not require them to think long and hard. Even still today as a new weapon becomes available old ones go into retirement and are replaced by weapons that will get the job done quicker. One weapon that is no longer around is the Trabuco.

The Trabuco is an ancient siege weapon that originated in China. Once the Chinese were ready to put the weapon up for sale, they sold it to the Arabs in the Middle East. When the Arabs received the weapons, they realized that the weapon had many flaws. They redesigned trabuco to function in a more beneficial way. After they made the changes and liked the work that they had done, they took the weapon to Europe to sell to the Europeans.


The Europeans were taken aback by the weapon. They were stunned by the amount of power the weapon had and the damage that it could potentially do. Trabuco was able to fire four shots per minute which were more than what they felt they needed to get a victory at the time. The machine required a number of people to operate it, but it still got the job done. Almost anything could be fired off of the weapon although commonly stones were fired. The Trabuco did a lot of damage in Europe during the Crusades according to Although the weapon did a lot of damage, it was not able to compare to gunpowder that had become available.

Visit for more details about Trabuco.

Clay Siegal, leading Seattle Genetics to greatness

Seattle Genetics is one of the most promising biotechnical companies in its region. Since its foundation in 1998, scientists at Seattle Genetics have dedicated themselves to developing drugs based on antibodies. These drugs, they say, function like smart bombs. They surround cancerous cells and deliver toxic payloads that make the cell destroy itself from inside.

Seattle genetics has about 11 drugs in the pipeline, four of which are almost ready for market: Adcetris, 33A, 22ME and LIV1. Adcetris has already been approved by the FDA, all that remains is a few more tests then it will be market worthy. For this reason, Seattle Genetics co-founder and CEO, Clay Siegal invests heavily on research and marketing. Mr Siegal hopes that once the drugs are ready, their sale will propel Seattle Genetics from biotech to being a leading pharmaceutical pharmacy. This has resulted in share prices going up and investors rushing in to buy shares.

However, some financial analysts say that the increase in share prices and the investor activity is due to speculation that Seattle Genetics will soon sell out. This has been the trend in the pharmaceutical industry. Many biotech companies sell to big pharmaceutical companies once they develop a drug or two that can be sold to the market. Clay Siegal assured his employees and investors that he has no intention to sell out to any company in the near future. He explained that his dream is to lead Seattle Genetics to become a global multi-product oncology company.

Clay siegal’s success in building Seattle Genetics to become Washington’s biggest biotech is emulating some of the things he learnt from biotech Genentech. Mr Siegal paid close attention to how Art Levinson, one of the founder of biotech Genentech structured the company. He paid close attention to how the committees were structured and run. He implemented some of the principles he learnt in his own company. Unlike most biotech companies, he decided not to focus on only one or two drugs. Like his mentor Art Levinson, he is not putting all his eggs in one basket.

Clay Siegal has guided Seattle Genetics in its fund raising activities and has been able to raise over 6.75 million dollars. Their fund raising activities have enabled them to conduct all their researches and tests. Before founding Seattle Genetics, Mr Siegal worked with Bristol-Myers Squibb Pharmaceutical Research Institute as a scientist for two years.